1. \> 24 hours of intensive care unit admission; 2. known glucose-6-phosphate dehydrogenase (g6pd) deficiency; 3. pregnancy; 4. known allergy to vitamin c; 5. known kidney stones within the past 1 year; 6. received any intravenous vitamin c during this hospitalization unless incorporated in parenteral nutrition; 7. expected death or withdrawal of life-sustaining treatments within 48 hours; 8. previously enrolled in this study; 9. previously enrolled in a trial with which co-enrolment is not allowed. the lovit trial has broad eligibility criteria and includes patients with a primary diagnosis of sepsis of any cause (including sepsis caused by viral pathogens as covid-19).

1. \> 24 hours of intensive care unit admission; 2. known glucose-6-phosphate dehydrogenase (g6pd) deficiency; 3. pregnancy; 4. known allergy to vitamin c; 5. known kidney stones within the past 1 year; 6. received any intravenous vitamin c during this hospitalization unless incorporated in parenteral nutrition; 7. expected death or withdrawal of life-sustaining treatments within 48 hours; 8. previously enrolled in this study; 9. previously enrolled in a trial with which co-enrolment is not allowed. the lovit trial has broad eligibility criteria and includes patients with a primary diagnosis of sepsis of any cause (including sepsis caused by viral pathogens as covid-19).

> 24 hours of intensive care unit admission; known glucose-6-phosphate dehydrogenase (g6pd) deficiency; pregnancy; known allergy to vitamin c; known kidney stones within the past 1 year; received any intravenous vitamin c during this hospitalization unless incorporated in parenteral nutrition; expected death or withdrawal of life-sustaining treatments within 48 hours; previously enrolled in this study; previously enrolled in a trial with which co-enrolment is not allowed. the lovit trial has broad eligibility criteria and includes patients with a primary diagnosis of sepsis of any cause (including sepsis caused by viral pathogens as covid-19).

> 24 hours of intensive care unit admission; known glucose-6-phosphate dehydrogenase (g6pd) deficiency; pregnancy; known allergy to vitamin c; known kidney stones within the past 1 year; received any intravenous vitamin c during this hospitalization unless incorporated in parenteral nutrition; expected death or withdrawal of life-sustaining treatments within 48 hours; previously enrolled in this study; previously enrolled in a trial with which co-enrolment is not allowed. the lovit trial has broad eligibility criteria and includes patients with a primary diagnosis of sepsis of any cause (including sepsis caused by viral pathogens as covid-19).

1. > 24 hours of intensive care unit admission; 2. known glucose-6-phosphate dehydrogenase (g6pd) deficiency; 3. pregnancy; 4. known allergy to vitamin c; 5. known kidney stones within the past 1 year; 6. received any intravenous vitamin c during this hospitalization unless incorporated in parenteral nutrition; 7. expected death or withdrawal of life-sustaining treatments within 48 hours; 8. previously enrolled in this study; 9. previously enrolled in a trial with which co-enrolment is not allowed. the lovit trial has broad eligibility criteria and includes patients with a primary diagnosis of sepsis of any cause (including sepsis caused by viral pathogens as covid-19).

1. > 24 hours of intensive care unit admission; 2. known glucose-6-phosphate dehydrogenase (g6pd) deficiency; 3. pregnancy; 4. known allergy to vitamin c; 5. known kidney stones within the past 1 year; 6. received any intravenous vitamin c during this hospitalization unless incorporated in parenteral nutrition; 7. expected death or withdrawal of life-sustaining treatments within 48 hours; 8. previously enrolled in this study; 9. previously enrolled in a trial with which co-enrolment is not allowed. the lovit trial has broad eligibility criteria and includes patients with a primary diagnosis of sepsis of any cause (including sepsis caused by viral pathogens as covid-19).